New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer
- 30 September 1991
- journal article
- review article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (9) , 1168-1172
- https://doi.org/10.1016/0277-5379(91)90318-8
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Cetus's Costly Stumble on IL-2Science, 1990
- Predominant Expression of T Cell Receptor V α 7 in Tumor-Infiltrating Lymphocytes of Uveal MelanomaScience, 1990
- BIOLOGICAL SIGNIFICANCE OF BETA hCG, HLA AND OTHER MEMBRANE ANTIGEN EXPRESSION ON BLADDER TUMOURS AND THEIR RELATIONSHIP TO TUMOUR INFILTRATING LYMPHOCYTES (TIL)International Journal of Immunogenetics, 1989
- Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating LymphocytesJNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2.The Journal of Experimental Medicine, 1986
- Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformationNature, 1984
- T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu miceNature, 1980
- Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.The Journal of Experimental Medicine, 1978